R1 Therapeutics, Inc., a Redwood City, CA-based biopharmaceutical company focused on developing therapies for kidney disease, extended its Series A financing to $80.5M, expanding on the $77.5M round announced in March 2026. The $3M expansion came from new investor Samsara BioCapital, who joined an investor syndicate including Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (formerly Symbiosis Capital Management), and U.S. Renal Care....See more